These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Bruckert E; Giral P; Tellier P Circulation; 2003 Jul; 107(25):3124-8. PubMed ID: 12835406 [No Abstract] [Full Text] [Related]
3. Long-term cholesterol-lowering effect of colestipol resin in humans. Gross L; Figueredo R J Am Geriatr Soc; 1973 Dec; 21(12):552-6. PubMed ID: 4584170 [No Abstract] [Full Text] [Related]
4. [Reduction of cholesterol and myocardial infarction. Big differences between different groups when it comes to the therapeutic effect]. Håkansson J Lakartidningen; 1997 Dec; 94(49):4619, 4622-3. PubMed ID: 9445934 [No Abstract] [Full Text] [Related]
5. [Preventing infarct by lowering LDL. Is 100 the upper limit for every diabetic patient?]. MMW Fortschr Med; 2003 Sep; 145(38):60. PubMed ID: 14603687 [No Abstract] [Full Text] [Related]
6. [Cholesterol lowering--Quo vadis? WOS (West of Scotland)--study of pravastin--a milestone in the prevention of myocardial infarct?!]. Fortschr Med Suppl; 1995; 170():1-7. PubMed ID: 9022407 [No Abstract] [Full Text] [Related]
7. Combined use of clofibrate and cholestyramine or DEAE sephadex in hypercholesterolaemia. Howard AN; Hyams DE Br Med J; 1971 Jul; 3(5765):25-7. PubMed ID: 4933388 [TBL] [Abstract][Full Text] [Related]
8. The effect of dextran 40 on hemorheological factors during the course of acute myocardial infarction. A preliminary report. Ditzel J; Bang HO; Thorsen N Bibl Anat; 1969; 10():132-6. PubMed ID: 4948068 [No Abstract] [Full Text] [Related]
9. [Lowering cholesterol for prevention of myocardial infarct and stroke? MRC/BHF Heart Protection Study]. Krone W Internist (Berl); 2003 Jun; 44(6):753-4. PubMed ID: 14567113 [No Abstract] [Full Text] [Related]
11. [Consequences of the "A to Z" studies: Cholesterol in acute coronary syndrome early and aggressive reduction?]. März W Herz; 2005 Feb; 30(1):78-80. PubMed ID: 16167397 [No Abstract] [Full Text] [Related]
12. Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. Prescrire Int; 1999 Aug; 8(42):116-20. PubMed ID: 11503831 [TBL] [Abstract][Full Text] [Related]
13. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Aronow WS; Ahn C Am J Cardiol; 2002 Jan; 89(1):67-9. PubMed ID: 11779527 [No Abstract] [Full Text] [Related]
14. Therapy and clinical trials. Game F Curr Opin Lipidol; 1996 Jun; 7(3):U105-7. PubMed ID: 8818523 [No Abstract] [Full Text] [Related]
15. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)]. Motz W MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487 [No Abstract] [Full Text] [Related]
16. [The cholesterol hypothesis has been proved true at last]. Huttunen J Duodecim; 1995; 111(5):385-6. PubMed ID: 8674438 [No Abstract] [Full Text] [Related]
17. Report on a double-blind investigation into the influence of -pyridyl-carbinol on the cholesterol level of the blood. Nelemans FA Arzneimittelforschung; 1972 Aug; 22(8):1410-3. PubMed ID: 4564745 [No Abstract] [Full Text] [Related]
18. Biphenabid (Probucol): a new hypocholesterolemic agent. Kalams Z; Dacquisto M; Kornett GS Curr Ther Res Clin Exp; 1971 Nov; 13(11):692-4. PubMed ID: 5000716 [No Abstract] [Full Text] [Related]
19. Probucol in the long-term treatment of hypercholesterolaemia. Polachek AA; Katz HM; Sack J; Selig J; Littman ML Curr Med Res Opin; 1973; 1(6):323-30. PubMed ID: 4589404 [No Abstract] [Full Text] [Related]
20. The statin era: in search of the ideal lipid regulating agent. Shepherd J Heart; 2001 Mar; 85(3):259-64. PubMed ID: 11179260 [No Abstract] [Full Text] [Related] [Next] [New Search]